Burden of respiratory syncytial virus hospitalisation among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies

被引:9
|
作者
Lanari, M. [1 ]
Anderson, E. J. [2 ,3 ]
Sheridan-Pereira, M. [4 ,5 ]
Carbonell-Estrany, X. [6 ]
Paes, B. [7 ]
Rodgers-Gray, B. S. [8 ]
Fullarton, J. R. [8 ]
Grubb, E. [9 ]
Blanken, M. [10 ]
机构
[1] S Orsola Univ Hosp, Dept Med & Surg Sci, Pediat Emergency Unit, Bologna, Italy
[2] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA
[3] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA
[4] Trinity Coll Dublin, Dept Paediat, Dublin, Ireland
[5] Coombe Women & Infants Univ Hosp, Dublin, Ireland
[6] Hosp Clin Barcelona, Inst Invest Biomed August Pi Suner IDIBAPS, Neonatol Serv, Barcelona, Spain
[7] McMaster Univ, Dept Pediat, Neonatal Div, Hamilton, ON, Canada
[8] Strategen Ltd, Winchester, Hants, England
[9] AbbVie Inc, Hlth Econ & Outcomes Res, N Chicago, IL USA
[10] Univ Med Ctr Utrecht, Div Pediat Immunol & Infect Dis, Utrecht, Netherlands
来源
EPIDEMIOLOGY AND INFECTION | 2020年 / 148卷
关键词
Epidemiology; Lower respiratory tract infection; Moderate-to-late preterm infants; Respiratory support; Respiratory syncytial virus; RSV hospitalisation; PRETERM INFANTS; COMPLETED WEEKS; RISK-FACTORS; INFECTION; MORBIDITY; MORTALITY; CHILDREN; DISEASE;
D O I
10.1017/S0950268820001661
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
To provide comprehensive information on the epidemiology and burden of respiratory syncytial virus hospitalisation (RSVH) in preterm infants, a pooled analysis was undertaken of seven multicentre, prospective, observational studies from across the Northern Hemisphere (2000-2014). Data from all 32(0)-35(6)weeks' gestational age (wGA) infants without comorbidity were analysed. RSVH occurred in 534/14 504 (3.7%) infants; equating to a rate of 5.65per100 patient-seasons, with the rate in individual wGA groups dependent upon exposure time (P= 0.032). Most RSVHs (60.1%) occurred in December-January. Median age at RSVH was 88 days (interquartile range (IQR): 54-159). Respiratory support was required by 82.0% of infants: oxygen in 70.4% (median 4 (IQR: 2-6) days); non-invasive ventilation in 19.3% (median 3 (IQR: 2-5) days); and mechanical ventilation in 10.2% (median 5 (IQR: 3-7) days). Intensive care unit admission was required by 17.9% of infants (median 6 days (IQR: 2-8) days). Median overall hospital length of stay (LOS) was 5 (IQR: 3-8) days. Hospital resource use was similar across wGA groups except for overall LOS, which was shortest in those born 35 wGA (median 3vs.4-6 days for 32-34 wGA;P< 0.001). Strategies to reduce the burden of RSVH in otherwise healthy 32-35 wGA infants are indicated.
引用
收藏
页数:7
相关论文
共 45 条
  • [11] Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis
    Robinson, Joan L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (07) : 1631 - 1632
  • [12] Impact of the risk scoring model on the cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks in Canada
    Lanctot, K. L.
    Paes, B.
    Francis, P. L.
    Chiu, A.
    Hui, C.
    Oh, P., I
    VALUE IN HEALTH, 2008, 11 (03) : A248 - A249
  • [13] Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis Reply
    Lanctot, Krista L.
    Paes, Bosco
    Hui, Charles
    Chiu, Aaron
    Tarride, Jean-Eric
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (07) : 1632 - 1633
  • [14] OPTIMIZING THE USE OF RISK FACTORS TO GUIDE THE COST-EFFECTIVE USE OF PALIVIZUMAB PROPHYLAXIS AGAINST SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN INFANTS BORN 32-35 WEEKS' GESTATIONAL AGE
    Keary, I
    Kang, J. M.
    Paes, B.
    Rodgers-Gray, B.
    Fullarton, J.
    Tarride, J. E.
    Yang, H. J.
    Chang, Y. S.
    Carbonell-Estrany, X.
    VALUE IN HEALTH, 2023, 26 (12) : S125 - S125
  • [15] A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP study
    Eric AF Simões
    Xavier Carbonell-Estrany
    John R Fullarton
    Johannes G Liese
    Jose Figueras-Aloy
    Gunther Doering
    Juana Guzman
    Respiratory Research, 9
  • [16] CREATING A UNIVERSAL RISK FACTOR MODEL FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) HOSPITALISATIONS IN 33-35 WEEKS' GESTATIONAL AGE (WGA) INFANTS IN THE NORTHERN HEMISPHERE
    Blanken, M.
    Paes, B.
    Lanari, M.
    Rodgers-Gray, B.
    Fullarton, J.
    Buchan, S.
    Rouffiac, E.
    Anderson, E.
    Carbonell-Estrany, X.
    EUROPEAN JOURNAL OF PEDIATRICS, 2016, 175 (11) : 1553 - 1553
  • [17] A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP study
    Simoes, Eric A. F.
    Carbonell-Estrany, Xavier
    Fullarton, John R.
    Liese, Johannes G.
    Figueras-Aloy, Jose
    Doering, Gunther
    Guzman, Juana
    RESPIRATORY RESEARCH, 2008, 9 (1):
  • [18] Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation
    Simoes, Eric A. F.
    Anderson, Evan J.
    Wu, Xionghua
    Ambrose, Christopher S.
    PLOS ONE, 2016, 11 (11):
  • [19] Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age
    X. Carbonell-Estrany
    L. Bont
    G. Doering
    J-B. Gouyon
    M. Lanari
    European Journal of Clinical Microbiology & Infectious Diseases, 2008, 27
  • [20] Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age
    Carbonell-Estrany, X.
    Bont, L.
    Doering, G.
    Gouyon, J-B
    Lanari, M.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2008, 27 (10) : 891 - 899